Durée de traitement des médicaments biologiques et des nouveaux immunomodulateurs dans la polyarthrite rhumatoïde, la spondylarthrite axiale, le rhumatisme psoriasique et le psoriasis - Étude de cohorte nationale à partir des registres DANBIO et DERMBIO
Semin Arthritis Rheum. 2022 doi: 10.1016/j.semarthrit.2022.151979
The authors reviewed drug survival of therapies across common inflammatory skin and joint conditions from national registries. The findings highlighted that despite the overlapping pathogenesis of these conditions there was little similarity in drug survival. This reinforces the need for an individualised treatment approach consistent with the underlying disease, patient profile and treatment history.